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Anthony H. GoldstoneThe large MRC/ECOG adult acute lymphoblastic leukemia (ALL) study establishes the value of sibling donor
allogeneic transplant in standard-risk patients demonstrating superior outcome to conventional chemother-
apy. The small but significant number of patients having matched unrelated donor (MUD) transplants on this
study protocol appear to do well, and may establish the value of such an approach for those without a sibling.
Reduced-intensity conditioning (RIC) conditioning might begin to address the transplant-related mortality
problems of the older patients. The youngest adults may not need a transplant at all. If they are now treated
on pediatric chemotherapy protocols, their outcome appears to improve significantly. The MRC/ECOG
study, the emerging MUD and RIC data all help establish allogeneic transplant more widely in this disease.
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We know that, in general, adult acute lymphoblas-
tic leukemia (ALL) has a very poor outcome compared
to that in children. It is clear, however, that the disease
is curable but only in a minority of patients. Approxi-
mately one-third are cured. This is despite the fact
that CR is very high, close to 90% in some studies
[1]. The problem is that few remain in remission de-
spite the fact that, as in pediatric ALL, the treatment
is initially very intensive throughout induction and
consolidation, and maintenance treatment typically
goes on for 2 further years or more. Thus, the evidence
is that many patients must be undertreated in that re-
lapse rates are high, yet it appears difficult to conceive
how chemotherapy could contribute any more without
the introduction of new drugs. The promise of a range
of effective new ones is not very great presently.
This disease is unusual compared to adult acutemy-
elogenous leukemia (AML) in that a significant propor-
tion of patients in complete remission (CR) die in CR.
This is not just in the group receiving allogeneic trans-
plant but also includes the groupnothaving a transplant.
The level of nonrelapse mortality (NRM) in the high-
risk ‘‘no-donor’’ group in UKALL 12/ECOG 2993 is
around 12% [1]. This is a level considerably higherDepartment of Haematology, University College London
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6/j.bbmt.2008.11.017than that usually seen in AML protocols. It means that
the net treatment-related mortality (TRM) associated
with transplant might be considered less unattractive
than initially thought; for instance, if 25%of a particular
group have aTRMassociatedwith transplant but would
have had a 12%TRManywaywithout it, then the net in-
cremental TRM of transplant of 25 2 12 5 113%. In
adult ALL where the CR rate is very high, we have few
totally new agents available, although there is a possibil-
ity that anti-CD 20 and other monoclonal antibodies,
for example, anti-CD22, may improve the freedom
from relapse in some patients already in remission.
At this stage, however, until we have totally novel agents
available, careful risk-benefit analysis is the only way to
assign current therapies appropriately. This raises the
possibility that the graft-versus-leukemia (GVL) effect,
well recognized in this disease [2] can be harnessed in
more patients safely to reduce the amount of relapse
without losing the patient to the problems of NRM
frequently associated with allogeneic transplantation
and unrelated donor transplantation in particular.
The value of unrelated transplants of potentially
reduced toxicity will need to be assessed [3].
In addressing the issue of how widespread the
applicability of allogeneic transplant is in adult ALL
the following questions need to be addressed:
1 Is there a GVL effect in adult ALL?
2 Is there evidence from large studies of a ‘‘donor
versus no-donor’’ effect beneficial in favor of sibling
allogeneic transplantation in adult ALL?
3 Is the constituency for allogeneic transplantation ex-
tended by the use of matched unrelated donors—is
there any evidence in favor of this?
4 Could the older and higher risk patients benefit
from allogeneic transplant—is there any evidence7
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Figure 1. MRC/ECOG study.
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in this disease?
5 Are there any clues as to who might be eligible par-
ticularly for a matched unrelated donor transplant?
6 Are young adults eligible for this approach, because
after all, their transplant-related mortality will be
low?
7 Is allogeneic transplant still relevant for Ph1ve
patients in the era of Tyrosine Kinase Inhibitors?
The best way to approach this debate is to address
these questions 1 by 1.
1. Is There a GVL Effect in Adult ALL?
Classical studies such as that as far back asWieden
et al. 1979 [2] show that there is a GVL effect in this
disease. This is clearly demonstrated in many other
studies, but particularly in the large MRC/ECOG
study that shows significant reduction in relapse from
the allogeneic effect in both standard and high-risk
groups.
2. Is There Evidence from Large Studies of
a Donor versus No-Donor Effect Beneficial in
Favor of Sibling Allogeneic Transplantation in
Adult ALL?
I think that the answer is, that, yes there is indeed
a benefit for sibling allogeneic transplant on a donor
versus no-donor basis.This is clearly shown in the large
MRC/ECOG study [1]. It is not clearly shown in
smaller studies such as that of Sebban et al. 1994 [4].
If one looks at the trends across a variety of studies,
then the significance of the superiority of transplants
on a donor versus no-donor basis seems to be clearly re-
lated to the size of individual studies, and therefore will
probably be confirmed and reflected in ameta-analysis,
bringing together the appropriate data.
Does the evidence in favor of donor versus no-do-
nor for survival in relation to sibling allograft occur
for all groups of patients? The answer is that this is
far from clear. Standard and high-risk patients are de-
fined differently in different studies. In the MRC/
ECOG study, for instance, all patients above 35 years
are high risk, all those with B cell disease or a white
count of .30  109L or T cell disease with a white
count of .100  109L with the Philadelphia chromo-
some or with T4 11, T8 14, complex karyotype, or
low hypodiploidy or triploidy. With any one of these
factors a patient becomes high risk. With none of
them a patient is standard risk. The large MRC/
ECOG study again clearly shows a benefit on a donor
versus no-donor basis for allogeneic sibling trans-
planted standard risk groups. It shows it less clearly
for high-risk groups. The standard-risk groups do
show a benefit for transplant of significance, whereas
the high-risk group do not. In a later trial by the French
group for high-risk patients, standard risk patientsreceiving only chemotherapy, on a donor versus
no-donor basis there is significantly better disease-free
survival (DFS) in the high-risk group with a donor. In
the Spanish PETHEMA group [5], high-risk patients,
defined slightly differently, did not show a superiorority
of transplants on a donor versus no-donor basis, even
when Ph1ve ALL patients were excluded.
These results in high-risk patients emphasize the
following problems. There is undoubtedly a signifi-
cant reduction in relapse seen in all these studies
via the allogeneic effect, but there are 2 problems.
First, the TRM in high-risk patients is such as to ab-
rogate the overall beneficial effect on survival in some
studies, and second, many of the studies are powered
with too small a number of patients to be able to
show significant differences between 1 group and
the other.3. Could Allo Be Extended by the Use of MUD
Donors?
In the MRC/ECOG study close to 70 patients had
an unrelated donor transplant (see Figure 1). For those
under 35 years the overall survival (OS) for a transplant
was 58%, and was much superior to that for those over
35 years, which was, in fact, 28%, but the small num-
bers mean that the P value was only 0.1. Relapse-free
survival (RFS) from transplant was 78% for the youn-
ger group versus 61% for the older group; P value
here was 0.3. If looked at in terms of Ph status, Ph1ve
patients had a survival of 37% and the Ph2ve patients
an encouraging outcome with an OS of 58% (P5 0.2).
In terms of RFS from transplant it was 63% for the
Ph1ve patients and 83% for the Ph2ve patients, with
a significant P value here of 0.04. There is quite clearly
other corrobative data here, suggesting encouraging
outcomes for the use of matched unrelated donors in
adults with this disease.Marks et al. [6] described unre-
lated donor transplants in 169 adult patients with ame-
dian age of 33 years. The TRM, RFS, andOS are 42%,
RIC allogeneic transplants in Adult ALL
• EBMT Registry 97 pts.  OS 31%
(Mohty et al 2008)
only 29% CRI. NRM 18%
• 27 1st CR pts. OS 31%
(Martino et al 2003)
•
•
Mexico 43 pts  2nd CR. OS 3 yrs 30%
(Guierrez-aguirre 2007)
 City of Hope 21 pts (10 1st CR) OS 77% 1 yr
(Stein 2007)
TRM 10%
IS THIS THE WAY FORWARD?
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gested that TRM was significantly higher with HLA
mis-matched donors and T cell depletion. In common
with other studies that appear to show the outcome
from matched unrelated donors (MUDs) to be little
different from that with sibling donors in this disease
[3]. There is considerable encouragement that unre-
lated donor transplant could be extended to those
who do not have a matched sibling, and this would sig-
nificantly shorten the overall treatment length for these
patients to around 6 months from diagnosis to trans-
plant from the 2 to 2.5 years required to give induction
consolidation and maintenance chemotherapy for
those not receiving a transplant.Figure 2. RIC allogeneic transplants in adult ALL.4. What About the Older and High-Risk
Patients—Is There Any Evidence for Use of
Reduced-Intensity Consolidation?
We can see from the above data, particularly the
MRC/ECOG data, that the problem is that the
TRM in the high-risk patients, with age as probably
the most significant factor, is such to abrogate the
overall benefit from transplant, so that with the
MUDs as with the sibling donors the age distribution
of the MRC/ECOG study and its relevance to OS is
clearly shown in the enclosed figure. Patients over
the age of 40 years have only a 23% survival in the
whole study, and those over the age of 50 years, 15%
at 5 years. For patients over 6- years, not studied by
MRC/ECOG, the OS is worse still. Because adult
ALL has a median age incidence of 60 years, the prob-
lem is that by conventional therapy the majority of pa-
tients, that is, those over 40, have a very poor outcome
indeed for treatments not involving transplant. With
allogeneic transplant there is clearly evidence in that
age group of a GVL effect, but of a high TRM. It is
possible that reduced-intensity conditioning (RIC) in
the older patient may represent a way forward with
the garnering of the allogeneic effect and a reduction
of the TRM. There are several early studies of small
groups of patients that might point to this approach
being useful (see Figure 2).5. Are There Any Clues As to Who Might Be
Eligible for a MUD?
Obviously, the prime candidates would be those
without a matched sibling, but still of an age group
able to tolerate any form of allogeneic transplant with-
out too much treatment-related risk. A greater risk
might be taken in those patients who have very high-
risk disease or who respond poorly to treatment when
it is initiated.There are some suggestions that any delay
in reaching first remission beyond 4 weeks might be in-
dicative of poor prognosis, but this was not substanti-
ated in the MRC/ECOG trial [7]. It appears that forpatients who are still MRD positive after 2 courses, it
may yet be worth while to go forward with a less
well-matched donor, understanding the risk, but con-
sidering that the outcome is still likely to be better
than with conventional therapy.6. Are Young Adults Eligible for This Approach?
It may be that the 1 group who should not be con-
sidered for allogeneic transplant are adolescents and
young adults with ALL. There have been a plethora
of publications recently by pediatric groups of appar-
ently superior outcome for adolescents and young
adults treated on typical paediatric regimens [8-12].
We are probably in a position where for adolescents
and young adults we cannot prospectively study the
apparent superiority of pediatric protocols to adult
protocols, and have therefore adopted pediatric proto-
cols despite the fact that all comparisons have been
retrospective and recognize the difficulty in comparing
adolescents and young adults treated in adult settings,
with those treated in pediatric units. Pediatric proto-
cols are rather generally more intensive with more
Asparaginase and perhaps fewer gaps in therapy. Keep-
ing to time adherence and adherence to dose schedules
may also be more common in paediatric approaches..
It is also quite clear that the biology of the disease
changes radically between 15 and 20 years and the dis-
tribution of these young adults between apparently
similar paediatric and adult protocols is never identi-
cal. For the young adults, however, in the large
MRC/ECOG study those with a donor still had a supe-
rior outcome compared to those who did not have a do-
nor. Although it seems likely that we will adapt for the
adolescents and young adults to the apparently supe-
rior paediatric protocols, it is too early to state un-
equivocally that an allogeneic transplant approach
should be abandoned in this group of patients, espe-
cially among adolescents and young adults at high risk.
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Ph1ve Adult ALL in the Era of Tyrosine Kinase
Inhibitors?
It has been true for some considerable time that al-
logeneic transplant represented the best and the only
likely way to cure Ph1ve ALL. The results of early al-
lograft have been not unpromising, and some time ago
led to the greater use of MUD transplants for those
without a matched sibling. These outcomes, too, in
the younger recipients, have been encouraging.
However, Imatinab and newer variants have in-
creased the CR rate in this subgroup and reduced the
amount of MRD after 1 to 2 months of treatment. It
seems likely that the combination of chemotherapy
and Imatinabwillmean that the risk of an unrelated do-
nor transplant is not worth taking for some patients
who might be cured by Imatinab and chemotherapy
alone.However, so far, data is inconclusive, and alloge-
neic transplant cannot be said to have outlived its
usefulness.CONCLUSION
The allogeneic effect clearly reduces relapse in
Adult ALL. Very large studies analysed on a ‘‘donor
versus no-donor’’ basis and meta-analysis are the
only types of data that can adequately address these is-
sues. Smaller studies will inevitably give ‘‘P’’ values that
do not infer significance and often seemingly give an
incorrect ‘‘steer’’ to tentative conclusions are the utility
of allogeneic transplant.
Although allogeneic transplant may well have less
of a role for the young adult under 25 years, between
25 years and 601 years encouraging data is emerging
of its value in those with and without a sibling donor.ACKNOWLEDGMENTS
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